Skip to main content

Published locations for Pembrolizumab is the first immune checkpoint inhibitor to receive approval for head and neck cancer

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Pembrolizumab is the first immune checkpoint inhibitor to receive approval for head and neck cancer

User login

  • Reset your password
  • /content/pembrolizumab-first-immune-checkpoint-inhibitor-receive-approval-head-and-neck-cancer-0
  • /jcso/article/126476/head-neck-cancers/pembrolizumab-first-immune-checkpoint-inhibitor-receive
  • /hematology-oncology/article/126476/head-neck-cancers/pembrolizumab-first-immune-checkpoint-inhibitor